Clinical Trialsfor AdvancedSolid Tumors
Ongoing
Clinical Study
Second Life Therapeutics is conducting a Phase 1/2a clinical trial to evaluate the safety and efficacy of off-the-shelf Leukocyte-Tells (SL-28) monotherapy in patients with advanced solid tumors.
About SL-28
SL-28 is an allogeneic, non-genetically modified cell therapy designed to treat a broad range of solid tumors.
In prior expanded access use,
SL-28 demonstrated
a near-universal response
rate in patients with diverse
advanced solid malignancies
—highlighting its transformative
potential.
Clinical trial
overview
Second Life Ttherapeutics is currently enrolling patients who have been diagnosed with advanced solid tumors in the first-in-human, Phase 1/2a clinical trial (NCT06800313). We are starting with Australian medical sites shortly, then expanding globally. The purpose of this open label, multi-center clinical trial is to evaluate the anti-tumor activity, safety, and pharmacokinetics of, single-agent SL-28 in patients with a diverse array of solid tumors. The study includes an initial Phase 1 dose escalation to determine recommended dose(s) for expansion of SL-28 as a monotherapy and Phase 2 expansion cohorts.
The study will enroll patients with advanced solid tumors, including those who failed previous lines of chemo- and immunotherapies.
Eligibility:
- Age:18+
- Sex:All
- StatusRecruiting
The study will enroll patients with the following tumor types:
Head and Neck
Head and neck squamous cell carcinoma
Thoracic
Small-cell lung cancer
Non-small cell lung cancer
Esophageal cancer
Gastrointestinal
Gastric cancer
Liver cancer
Colorectal cancer
Pancreatic adenocarcinoma
Genitourinary
Bladder cancer
Renal cell carcinoma
Prostate cancer
Gynecologic
Ovarian cancer
Endometrial cancer
Breast and Skin
Breast cancer
Melanoma
+
Other
To learn more about the trial, please email to: clinical@secondlifetx.com Further details for healthcare providers can be accessed below: www.clinicaltrials.gov
About SL-28
A New Mechanism of Action
Leukocyte-Tells (SL-28)
Represent a first-in-class, allogeneic, non-genetically modified cell therapy for advanced solid tumors. For the first time, immune cells have been engineered to modulate Cell Memory through the newly discovered Universal Receptive System and Teazeled (TezR) receptors.
Safety and Efficacy
Represent a first-in-class, allogeneic, non-genetically modified cell therapy for advanced solid tumors. For the first time, immune cells have been engineered to modulate Cell Memory through the newly discovered Universal Receptive System and Teazeled (TezR) receptors.
Disclaimer
Leukocyte-Tells (SL-28) is an investigational drug that has not been approved by any regulatory agency. The safety and effectiveness have not been fully established.
Case reports
Promising Compassionate
Use Results
For patients who have already tried multiple therapeutic options, early clinical results with Leukocyte-Tells (SL-28) offer new hope. Recent data demonstrated durable responses in patients with advanced solid tumors who had previously failed both chemotherapy and immunotherapy. SL-28 therapy was also very well tolerated, with no patients discontinuing due to side effects. These results highlight the transformative potential of SL-28 for patients with diverse tumor types who urgently need new treatment options.
Disclaimer
Leukocyte-Tells (SL-28) is an investigational drug that has not been approved by any regulatory agency. The safety and effectiveness have not been fully established.
Why SL-28
Is Different
01
SL-28 is changing the paradigm of the therapy of advanced solid tumors. It is based on a proprietary technology, for the first time, regulating and orchestrating multiple anticancer processes in immune cells - including Cell Memory - which has never been done before in medical history.
02
SL-28 has multiple novel anticancer mechanisms not found in other cell therapies. SL-28 are non-genetically modified cells, which put them apart from CAR-T, and they are not delivered from the same patient like CAR-T or TIL therapy.
03
SL-28 is a total, standalone type of cell therapy, offering a groundbreaking approach for patients with advanced solid tumors - even those who failed previous therapies and are considered resistant.
How it works
?
Allogeneic, immediate
off-the shelf therapy
Overcoming Delays in Cell Therapy
Most cell-based therapies require harvesting, modifying, and reinfusing a patient’s own cells, a process that can take weeks - or even months. For patients with advanced cancers, this is time they do not have.
Immediate Access with SL-28
SL-28 eliminates these delays. As an off-the-shelf therapy, it is immediately available for patients who need urgent anti- cancer therapy, allowing treatment to begin without the long manufacturing timelines of conventional, autologous cell therapies.
Healthy donors
Leukapheresis
Isolate white blood cells (WBC)
WBCs ex vivo through activated by targeting novel TezR receptors
Increased anticancer activity
Reduced HLA reactivity
Scalable Allogeneic WBC Manufacturing
Fill finish of 1000+ doses/batch
SL-28 Immediate Infusion for many patients